Close

Epizyme (EPZM) Presents Data on PRMT5 Inhibitor EPZ015666

December 8, 2014 1:33 PM EST Send to a Friend
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login